Real-World Analysis Reveals Cardiac Failure Risk Varies Significantly Among Breast Cancer Therapies
Key Insights
A comprehensive analysis of 8,565 cardiac failure (search) cases from three major adverse event databases reveals significant differences in heart failure risk among breast cancer (search) treatments.
Trastuzumab showed consistently strong cardiac failure (search) signals across all databases, while CDK4/6 (search) inhibitors and immune checkpoint inhibitors demonstrated low or inverse risk ratios.
The study found that everolimus, sacituzumab govitecan, and atezolizumab had the highest death proportions at 20.1%, 22.6%, and 23.5% respectively.
A large-scale real-world analysis examining cardiac failure (search) risks associated with novel breast cancer (search) therapies has revealed significant drug-specific differences in cardiovascular safety profiles, with trastuzumab showing consistently strong cardiac failure signals across multiple international databases.
Researchers from Shenzhen Baoan People's Hospital (search) and Sun Yat-Sen University Cancer Center (search) conducted a comprehensive disproportionality analysis using individual case safety reports from three major adverse event databases: the FDA Adverse Event Reporting System (FAERS), Canada Vigilance Adverse Reaction Database, and Japanese Adverse Drug Event Report database, spanning from January 2004 to March 2025.
Trastuzumab Shows Strongest Cardiac Risk Signals
The analysis identified 8,565 cardiac failure (search) cases across the three databases, with trastuzumab exhibiting consistently strong signals in all regions. The reporting odds ratios (RORs) for trastuzumab were 2.94 in FAERS, 6.15 in the Canadian database, and 7.05 in the Japanese database, indicating a substantially elevated risk of cardiac failure compared to other treatments.
Pertuzumab and everolimus showed variable significance across databases, while CDK4/6 (search) inhibitors and immune checkpoint inhibitors (ICIs) demonstrated low or inverse RORs, suggesting a lower association with cardiac failure (search) events.
Time-to-Onset and Mortality Patterns Vary by Drug Class
The study revealed distinct temporal patterns in cardiac failure (search) development across different drug classes. Monoclonal antibodies showed the longest median time-to-onset (TTO), while antibody-drug conjugates (ADCs) and immune checkpoint inhibitors had shorter onset times.
Mortality outcomes varied significantly among treatments. Everolimus showed the highest death proportion at 20.1%, followed by sacituzumab govitecan at 22.6% and atezolizumab at 23.5%. In contrast, trastuzumab had a notably lower death proportion of 8.75%, despite its strong association with cardiac failure (search) development.
HER2-Targeted Agents Present Higher Risk Than Traditional Therapies
The analysis demonstrated that HER2 (search)-targeted agents had higher reporting signals for cardiac failure (search) compared to traditional chemotherapies, highlighting the cardiovascular risks associated with targeted breast cancer (search) treatments. This finding underscores the complex relationship between therapeutic efficacy and cardiovascular safety in modern oncology.
Clinical Implications for Treatment Planning
The study's findings emphasize the importance of individualized cardiovascular risk assessment during treatment planning and monitoring for breast cancer (search) patients. The drug-specific differences in cardiac failure (search) risk profiles suggest that oncologists should consider baseline cardiovascular status and implement appropriate monitoring strategies based on the specific therapeutic regimen.
The research provides crucial real-world evidence to inform clinical decision-making, particularly for patients with pre-existing cardiovascular conditions or those at higher risk for cardiac complications. The comprehensive nature of the analysis, drawing from multiple international databases over more than two decades, offers robust evidence for understanding the cardiovascular safety landscape of modern breast cancer (search) therapies.